3. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202–452–3204

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: October 23, 1998.

Barbara R. Lowrey,

Associate Secretary of the Board.

[FR Doc. 98–28915 Filed 10–23–98; 3:54 pm]

BILLING CODE 6210–01–M

GENERAL SERVICES ADMINISTRATION

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Federal Technology Service, GSA.

ACTION: Notice.

SUMMARY: The General Services Administration is announcing that a collection of information entitled ''Blue Pages Project'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35).

FOR FURTHER INFORMATION CONTACT: Beth Johnson, Federal Technology Service (202) 501–1938.

SUPPLEMENTARY INFORMATION: In the **Federal Register** on August 14, 1998 (63 FR 43715), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the Paperwork Reduction Act. An agency may not conduct or sponsor, and a person if not required to respond to a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and assigned OMB control number 3090–0269. The approval expires on February 28, 1999.

Dated: October 19, 1998.

Ida M. Ustad,

Deputy Associate Administrator, Office of Acquisition Policy.

[FR Doc. 98–28721 Filed 10–26–98; 8:45 am]

BILLING CODE 6820–61–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[Document Identifier: HCFA–R–253 and HCFA–R–251]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

(1) Type of Information Request: Extension of a currently approved collection.

Title of Information Collection: Call-Back Survey of Callers to the Medicare+Choice Toll-free Line.

Form Number: HCFA–R–253 (OMB approval #: 0938–0737).

Use: The primary purpose of the call-back survey is to obtain information from callers about their satisfaction with the Medicare+Choice toll-free line. This information will be used to identify problems and make recommendations for ways of improving the service provided through the Medicare+Choice toll-free line.

Frequency: On occasion.

Affected Public: Individuals or Households.

Number of Respondents: 1,050.

Total Annual Responses: 1,050.

Total Annual Hours Requested: 175 hours.

(2) Type of Information Collection Request: Extension of a currently approved collection.

Title of Information Collection: Medicare & You Bounce Back Survey Form.

Form No.: HCFA–R–251 (OMB# 0938–0740).

Use: The primary purpose of the bounce back form is to provide HCFA feedback from users of the Medicare+Choice handbook. The information collected through the bounce back form will be used in conjunction with other information collected in the States piloting Medicare & You to make revisions for future publications of the Medicare & You, Medicare+Choice handbook.

Frequency: On occasion.

Affected Public: Individuals or Households, Businesses or other For-profit.

Number of Respondents: 9,855.

Total Annual Responses: 9,855.

Total Annual Hours: 986.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access HCFA's Web Site address at http://www.hcfa.gov/regs/prdact95.htm, or E-mail your request, including your address, phone number, OMB number, and HCFA document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards, Attention: Dawn Willinghan, Room N2–14–26, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: October 20, 1998.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards.

[FR Doc. 98–28741 Filed 10–26–98; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[Document Identifier: HCFA–R–0185]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

AGENCY: Health Care Financing Administration.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the

following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Extension of a currently approved collection; Title of Information Collection: Granting and Withdrawal of Deeming Authority to Private Nonprofit Accreditation Organizations and of CLIA Exemption Under State Laboratory Programs and Supporting Regulations in 42 CFR 493.551–493.557; Form No.: HCFA-R–185 (OMB# 0938–0686); Use: The information required is necessary to determine whether a private accreditation organization/State licensure program standards and accreditation/licensure process is equal to or more stringent than those of CLIA. This information also provides a CLIA exemption of laboratories in a State that applies licensure requirements that are equal to or more stringent than those of CLIA; *Frequency:* Initial Application/as needed; *Affected Public*: Not-for-profit institutions, and State, Local, or Tribal Government; *Number of Respondents:* 22; *Total Annual Responses:* 11; *Total Annual Hours:* 2,112.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access HCFA's Web Site address at http://www.hcfa.gov/regs/prdact95.htm, or E-mail your request, including your address, phone number, OMB number, and HCFA document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to the OMB desk officer: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: October 19, 1998.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards.

[FR Doc. 98–28739 Filed 10–26–98; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Opportunities for Cooperative Research and Development Agreements

National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADAs) for the development and evaluation of allogeneic whole melanoma cell vaccines based on the expression of shared tumor-associated antigens in association with GM–CSF as potential treatments for cancer.

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice of Opportunities for Cooperative Research and Development Agreements.

SUMMARY: Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) seeks Cooperative Research and Development Agreements (CRADAs) with pharmaceutical or biotechnology companies.

Any CRADA for the biomedical use of this technology will be considered. The CRADAs would have an expected duration of three (3) to five (5) years. The goals of the CRADAs include the rapid publication of research results and timely commercialization of products, diagnostics and treatments that result from the research. The CRADA Collaborators will have an option to negotiate the terms of an exclusive or nonexclusive commercialization license to subject inventions arising under the CRADAs.

EFFECTIVE DATE: Organizations must submit a proposal summary preferably one page or less, to NCI within two weeks from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest.

ADDRESSES: Proposals and questions about this CRADA opportunity may be addressed to Dr. Suzanne M. Frisbie, Technology Development & Commercialization Branch, National Cancer Institute, 6120 Executive Blvd., Suite 450, Rockville, MD 20852, Telephone: (301) 496–0477, Facsimile: (301) 402–2117.

SUPPLEMENTARY INFORMATION:

Technology Available

Using recombinant DNA technology, NCI has cloned a number of shared (commonly expressed) melanoma-associated antigens recognized by immune cells derived from melanoma patients and thought to be associated with tumor regressions in patients undergoing immunotherapy. These antigens include MART–1, gp100, gp75, tyrosinase, TRP–2, and others. NCI has extensive experience in the design and conduct of clinical trials to assess the potential efficacy of vaccine treatments, and has unique expertise in developing *in vitro* immunologic assays to monitor the results of such treatments. NCI has identified select cultured melanoma cell lines which express a plurality of shared melanoma antigens and desires to develop these cell lines, or similar cell lines, as allogeneic whole cell vaccines for the treatment of melanoma. Furthermore, based on extensive preclinical experimentation demonstrating the unique efficacy of whole tumor cell vaccines genetically engineered to secrete large amounts of the immunostimulatory cytokine GM–CSF, NCI desires to administer allogeneic whole melanoma cell vaccines engineered to secrete this cytokine. Published data document the importance of $CD4^+$ T helper cells in anti-tumor immune responses in the context of GM–CSF-secreting whole tumor cell vaccines. NCI has special expertise in defining T helper cell responses to human cancers and is on the forefront of developing biochemical and molecular cloning strategies for identifying novel MHC class II-restricted tumor antigens. Thus, the selected sponsor will collaborate in a project aimed to develop GM–CSF-secreting melanoma cell lines for use in human vaccination trials, to monitor the immunological effects of such vaccination, and to develop improved *in vitro* methods for characterizing T helper cell responses to such a vaccine.

The role of the National Cancer Institute in this CRADA may include, but not be limited to: